Leadership Changes at Legend Biotech and Sarepta Therapeutics
Legend Biotech has experienced an unexpected leadership change as its CEO Ying Huang resigned abruptly on July 24. The departure was not due to any disagreements with the company, according to a filing from July 27. Alan Bash, current president of Legend's Carvykti Business Unit, will serve as interim CEO while a search for permanent leadership is underway. In contrast, Sarepta Therapeutics has announced its new CEO following an anticipated transition. Michael Severino, former CEO of Tessera Therapeutics and ex-president of AbbVie, was appointed after a five-month search process to replace outgoing CEO Doug Ingram, who retired due to personal reasons. Severino brings over 25 years of biopharma experience and will lead Sarepta during a critical period following regulatory challenges with its DMD gene therapy Elevidys.
Topics: Biotech Cell therapy Legend Biotech Sarepta Therapeutics